Skip to main content
. 2021 May 28;39(28):3149–3160. doi: 10.1200/JCO.20.03048

FIG 3.

FIG 3.

Outcomes for patients with HR versus NHR patients with KMT2A-r AML by GO exposure. (A) EFS from study entry and (B) RR from CR. CR, complete remission; EFS, event-free survival; GO, gemtuzumab ozogamicin; HR, higher risk; KMT2A-r, KMT2A-rearranged; NHR, not high-risk; No-GO, did not receive GO; RR, relapse risk.